LOGIN  |  REGISTER
Viking Therapeutics

Akoya Biosciences to Participate at Three Upcoming Investor Conferences

July 26, 2023 | Last Trade: US$2.11 0.01 -0.47

MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.

  • Canaccord 43rd Annual Growth Conference
    Fireside Chat on Wednesday, August 9th at 9:00 AM ET
  • UBS MedTech, Tools & Genomics Summit
    Fireside Chat on Thursday, August 17th at 3:00 PM PT
  • Morgan Stanley 21st Annual Global Healthcare Conference
    Fireside Chat on Wednesday, September 13th at 10:10 AM ET

A live and archived webcast of the events will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit http://www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Christine Quern
(617) 650-8497
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB